Acrobiosystems Co

Acrobiosystems Co Book Value per Share

The Book Value per Share of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 15.90 CNY. In the previous year, Book Value per Share was 15.65 CNY — a change of 1.61% (higher).

Book Value per Share

15.90CNY

YoY

1.61%

Last updated:

Book Value per Share of Acrobiosystems Co is 2025 15.90 CNY. Book Value per Share of Acrobiosystems Co was 2024 15.65 CNY. It decreases by 1.61% higher compared to the previous year.

The Acrobiosystems Co Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
0.44 CNY
Jan 1, 2019
0.58 CNY
Jan 1, 2020
1.20 CNY
Jan 1, 2021
14.76 CNY
Jan 1, 2022
15.33 CNY
Jan 1, 2023
15.49 CNY
Jan 1, 2024
15.65 CNY
Jan 1, 2025
15.90 CNY
The Acrobiosystems Co Book Value per Share history
YEARBook Value per ShareYoY
15.90CNY+1.61%
15.65CNY+1.01%
15.49CNY+1.03%
15.33CNY+3.90%
14.76CNY+1,131.61%
1.20CNY+105.67%
0.58CNY+32.85%
0.44CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Book Value per Share of Acrobiosystems Co is 15.90 CNY in 2025.

Book Value per Share of Acrobiosystems Co changed from 15.65 CNY to 15.90 CNY, representing a 1.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co